Display options
Cite
Smith DA. Design of drugs through a consideration of drug metabolism and pharmacokinetics. Eur J Drug Metab Pharmacokinet. 1994;19(3):193-9doi: 10.1007/BF03188921.
Smith, D. A. (1994). Design of drugs through a consideration of drug metabolism and pharmacokinetics. European journal of drug metabolism and pharmacokinetics, 19(3), 193-9. https://doi.org/10.1007/BF03188921
Smith, D A. "Design of drugs through a consideration of drug metabolism and pharmacokinetics." European journal of drug metabolism and pharmacokinetics vol. 19,3 (1994): 193-9. doi: https://doi.org/10.1007/BF03188921
Smith DA. Design of drugs through a consideration of drug metabolism and pharmacokinetics. Eur J Drug Metab Pharmacokinet. 1994 Jul-Sep;19(3):193-9. doi: 10.1007/BF03188921. PMID: 7867661.
Copy Download .nbib Format: NLM
Share it on

Eur J Drug Metab Pharmacokinet. 1994 Jul-Sep;19(3):193-9. doi: 10.1007/BF03188921.

Design of drugs through a consideration of drug metabolism and pharmacokinetics.

European journal of drug metabolism and pharmacokinetics

D A Smith

Affiliations

  1. Department of Drug Metabolism, Pfizer Central Research, Sandwich, Kent, U.K.

PMID: 7867661 DOI: 10.1007/BF03188921

Abstract

Drug metabolism input to the discovery process has been to date largely on an empirical case by case basis. Considerable advances have been made, such that basic rules can be applied to the behaviour of a compound in man based on physico-chemistry and structure. This is particularly true in the area of the cytochrome P-450 enzymes, the principal enzymes involved in the primary clearance of drugs. The major human forms, CYP2D6, CYP2C9 and CYP3A4 all have distinct substrate preferences which are being catalogued and rationalised. Such understandings will not only impact on existing drugs. Since the enzymes and systems will remain the same, these understandings can be applied to the design of molecules for the targets of the future, whilst the structure activity relationships of those targets are being researched and revealed.

References

  1. Drug Metab Dispos. 1990 Sep-Oct;18(5):711-9 - PubMed
  2. Pharmacogenetics. 1993 Feb;3(1):1-18 - PubMed
  3. J Med Chem. 1992 Feb 21;35(4):756-72 - PubMed
  4. Xenobiotica. 1990 Nov;20(11):1187-99 - PubMed
  5. Xenobiotica. 1988 Mar;18(3):331-50 - PubMed
  6. Pharm Res. 1991 Dec;8(12 ):1477-81 - PubMed
  7. Clin Pharmacokinet. 1989 Feb;16(2):100-28 - PubMed
  8. J Med Chem. 1993 Jul 23;36(15):2059-65 - PubMed
  9. Clin Pharmacokinet. 1983 Jul-Aug;8(4):297-331 - PubMed
  10. Br J Clin Pharmacol. 1988 Mar;25(3):387-96 - PubMed
  11. Biochem Pharmacol. 1992 Dec 1;44(11):2089-98 - PubMed
  12. Xenobiotica. 1992 Sep-Oct;22(9-10):1195-205 - PubMed
  13. J Med Chem. 1987 Jun;30(6):1003-11 - PubMed
  14. J Pharmacol Toxicol Methods. 1993 Apr;29(2):77-83 - PubMed
  15. FASEB J. 1990 May;4(8):2453-9 - PubMed
  16. Xenobiotica. 1992 Jul;22(7):743-55 - PubMed
  17. J Med Chem. 1993 Apr 30;36(9):1136-45 - PubMed
  18. J Med Chem. 1993 Feb 19;36(4):449-59 - PubMed

Substances

MeSH terms

Publication Types